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Authors’ reply 
 
We appreciate the  response of Osterholm and colleagues to our re-analysis of the clinical 
evidence of influenza vaccine effectiveness in elderly adults, accumulated during the past 40 
years.  Osterholm et al. have raised four objections against our main conclusion that 
vaccination reduces influenza infection and influenza-related disease in elderly adults. In our 
opinion, these objections do not invalidate our conclusion. 
 
1. Antibody ceiling bias 
 
As stated by Osterholm et al, some studies did indeed rely on antibody titre rises in pairs 
of pre- and post-season sera to detect influenza infections, in particular the randomised 
controlled trial of Govaert et al. [1] from the early 1990s when advanced detection 
methods, like the real-time polymerase chain reaction (rtPCR), were not yet available. 
An antibody ceiling bias may have affected Govaert et al’s estimation of serological 
vaccine efficacy, but has likely not entirely invalidated it. More importantly, the 
protection from influenza-like illness assessed clinically without serology, was also 
significant and pointed in the same direction as the serological estimate. 
 
 
2. Biological vaccine efficacy and cut-off level for seroprotection 
 
We agree with the cited statement of the Food and Drug Administration, and therefore 
we have not defined biological vaccine efficacy by any cut-off HI antibody titre. We have 
also found that the association between protection and a specific antibody cut-off point 
is poor [2]. Pre-season HI antibody and protection are strongly connected in a curvilinear 
manner: the higher the antibody titre, the lower the chance of infection [3]. Estimation 
of protection from antibody titres is possible if the entire protection curve (rather than a 
single cut-off point) is considered. In our Supporting Material 2, last paragraph, we have 
covered this subject. So, this objection must be a misunderstanding. Incidentally, the 
literature retrieval performed by the Cochrane Collaboration (and on which we base our 
entire re-analysis) already excluded pure antibody vaccination studies (those reporting 
pre- and post-vaccination titres without clinical follow-up). Consequently, the data used 
in our article consists entirely of follow-up outcomes. 
 
 
3. All-cause mortality studies 
 
We could not agree more with Osterholm et al. that vaccine effectiveness estimated 
from observational studies of all-cause mortality are likely to be heavily biased. We 
found a mean effectiveness of 48% in the studies reviewed, contrasting sharply with the 
average effectiveness figure of 4.6% from the exceptional study by Fireman et al. [4]; we 
explain the discrepancy as a healthy user effect, according to Simonson et al. [5]. 
Consequently, we excluded all-cause mortality studies from our main analysis. What 
Osterholm et al. are presenting as disagreement between their and our position, is in 
fact, from our perspective, a complete agreement. 
 
 
4. Studies applying the test-negative design 
 
The test-negative design has increasingly been used during the last years and is very 
promising, indeed. The main theoretical problem of this design is the same as in all 
observational studies: the exposure risk may not be the same in vaccinated and 
unvaccinated persons [6] potentially leading to a large variation of the effectiveness 
estimates between places and seasons. Single study results from a limited number of 
seasons, like the 27% and 9% point estimates mentioned by Osterholm et al., should 
therefore be interpreted with caution, and cannot easily be compared with our averages 
and ranges based on 40 years of observations across numerous studies. We refer to 
Figure 2 of our article: note how large the ranges of the three described effectiveness 
measures are, compatible with large inter-season variation. The point estimates quoted 
by Osterholm et al. are situated within these ranges. Only the entirety of many studies 
from many years reveals the complete pattern of vaccine effectiveness and allows the 
estimation of an average biological vaccine efficacy. 
 
 
Thus, we feel that the four objections of Osterholm et al. do not challenge, let alone 
disprove, our main conclusion that influenza vaccination significantly reduces the risks of 
infection and disease in elderly adults, even with the imperfect formulations of the 
inactivated vaccines in common usage during the last four decades. New generation 
vaccines, specifically developed for elderly adults, should further improve protection. We 
support policies to vaccinate elderly people against influenza. 
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